Fig. 5

Dysregulation of TIMP1 exon 4–5 splicing in CRC. A Genome browser view depicts the coverage of exons in TIMP1 in representative normal and tumor tissues. B Distribution of PSI value of TIMP1 exon 4–5 skip events in CRC and adjacent normal tissues, P values were calculated by two-sided Mann–Whitney test, *** P < 0.0001. C Expression level of full-length TIMP1 transcript (TIMP1-FL, left) or TIMP1 transcript with exon 4 and 5 exclusion (TIMP1 Δ4-5, right) in CRC and adjacent normal tissues, P values were calculated by two-sided Mann–Whitney test, *** P < 0.001. D Kaplan–Meier survival analysis of the correlation between TIMP1-FL (left) or TIMP1 Δ4-5 (right) expression and patients’ overall survival rate, log-rank test. E The Scheme describes the primer design strategy to characterize the exon 4 and 5 inclusion or exclusion of TIMP1. F Sanger sequencing analysis indicated the exon3-exon6 junction in NCM-460 and SW480 cells. G RT-PCR results of TIMP1 in different CRC cancer cell lines and normal human colon mucosal epithelial cell line. H qRT-PCR results of TIMP1-FL (left) or TIMP1 Δ4-5 (right) expression in CRC cancer cell lines and normal human colon mucosal epithelial cell line. P values were calculated by two-sided Student’s t test, * P < 0.05, ** P < 0.01, *** P < 0.001. I qRT-PCR results depict the ratio of transcripts with or without exon 4–5 in 12 pairs of CRC and adjacent normal tissues. P values were calculated by two-sided Student’s t test, ** P < 0.01